Indaptus Q3 10-Q: Going-Concern Doubt Resolved, $26.6M Cash, No Active Trials
INDP has more than doubled off its 52-week low of $0.92 on light trading volume (0.1× avg).
Summary
Indaptus reported Q3 2026 results with the prior going-concern doubt resolved on $26.6M cash plus $4.0M in CDs and $3.5M received in October, funding operations for at least a year. With no active clinical trials and R&D down 82%, the story now hinges on management finding a strategic transaction.
Key Events · Earnings and Guidance · INDP
-
Going-Concern Doubt Resolved
Management states the conditions that previously raised substantial doubt about the ability to continue as a going concern have been resolved, based on $26.6M cash, $4.0M in short-term investments and $3.5M received in October 2026, funding operations for at least one year from issuance with no assumed future financing.
-
No Active Clinical Programs
Decoy20 enrollment is discontinued, no participants remain in any study, and there are no current plans to initiate a new trial; the company is evaluating strategic alternatives including a Post-Investment Transaction (an investment in or acquisition of an operating business).
-
Q3 Loss Narrows on Cost Cuts
Q3 2026 net loss was $1,048,778 ($0.01 per share) versus $2,975,117 ($2.98 per share) a year earlier; R&D fell 82% to $271,204 and G&A fell 24% to $864,663. Nine-month net loss was $5,384,709 versus $12,736,466.
-
$24M Placement Closed October 16
The September 2026 private placement of 20,338,974 shares for approximately $24.0M gross closed on October 16, 2026 with all shares issued; $20.5M was received before September 30 and $3.5M in October.
Analysis · INDP · Life Sciences
The headline here is that the going-concern warning previously disclosed is now resolved: $26.6M cash plus $4.0M in certificates of deposit plus the $3.5M collected in October funds operations for at least a year from issuance, without assuming any future financing. That buys time, but there are no active clinical programs — Decoy20 enrollment is discontinued, no participants remain, and management has no plans to start a new trial — so the equity is now a bet on a strategic transaction (an investment in or acquisition of an operating business) rather than on a drug. The cost base has been cut hard to match: Q3 R&D fell 82% to $271,204 and G&A fell 24% to $864,663, shrinking the quarterly net loss to $1,048,778 from $2,975,117. The dilution already happened — 133,242,324 shares outstanding versus 2,167,324 at year-end after 111,000,000 preferred shares converted and two placements closed — and the $100M ATM remains an overhang on top of that.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDP was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $483.8M. The 52-week trading range was $0.92 to $5.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.